Fatigue Severely Impacts Quality of Life, Work Productivity in MS
Patients having a relapse, confirmed disability accumulation, or worsening in fatigue had significant negative impact on each of the work productivity and activity impairment measures.
Prescribing DMT in Radiologically Isolated Syndrome: Ilena George, MD
The neurologist from Massachusetts General Hospital discussed physician rationales behind prescribing DMT use in RIS.
Multiple Sclerosis Care Professionals Satisfied With Clinical Video Telemedicine Visits
Researchers found that the percentage of telemedicine visits increased from 15% to 72.8% during the COVID-19 pandemic.
Mechanical Thrombectomy Efficacious in Distal Medium Vessel Occlusion
Researchers found that higher NIHSS scores on admission and a successful first-pass effect were predictors of reaching early neurological improvement.
NeurologyLive Friday 5 — March 5, 2021
Take 5 minutes to catch up on NeurologyLive's highlights from the week ending March 5, 2021.
ACTRIMS 2021 Post-Conference Expert Perspective: Jeffrey Cohen, MD
The president of the Americas Committee for Treatment and Research in MS discusses his takeaways from this year’s virtual forum.
Advanced Alzheimer Flortaucipir Pattern Associated With Increased Risk of Clinical Progression
At 18-month follow-up, 70% of those with an advanced Alzheimer disease pattern had 1 point or more increase in CDR-SB, an event predefined as clinically meaningful deterioration.
The Need to Improve Poststroke Care: Mijail Serruya, MD, PhD
The assistant professor of neurology at Thomas Jefferson University discussed areas of poststroke care that need improvement including a more streamlined process.
Understanding the Momentum in the Autoimmune Encephalitis Research Community
The assistant professor of neurology at Mayo Clinic discussed his presented talk at ACTRIMS Forum 2021 on autoimmune encephalitis.
The History of Exercise Interventions to Prevent Alzheimer Disease
The duo from Cleveland Clinic discussed the reasons for choosing cycling as part of their newly initiated clinical trial, as well as what has been observed for home-based exercise interventions.
African American Patients With MS Switch to Ocrelizumab Treatment Earlier than Caucasian Patients
Researchers also found that patients with progressive MS had longer disease duration before starting DMTs than those with relapsing MS.
Tumor Necrosis Factor Signaling Inhibition Fails to Prevent or Delay Parkinson Disease
Genetically-index TNF-TNFR1 signaling blockade predicted reduced risk of Crohn disease and ulcerative colitis, and increased multiple sclerosis risk.
The Economic Burden of SMA Prior to Treatment Approvals: Lisa Belter, MPH
The director of research analytics at Cure SMA discussed her research on the economic burden and costs patients with spinal muscular atrophy and their caregivers face.
Human Oligodendrocyte Differences Due to Environmental Signals Rather Than Lineage
Researchers used single-cell RNA sequencing on adult, pediatric, and infant surgical tissues to study oligodendrocyte types in order to better understand multiple sclerosis.
Pegunigalsidase Alfa Demonstrates Efficacy in Phase 3 Fabry Disease Study
Protalix BioTherapeutics intends to report final data on the agent, also known as PRX-102 in the second half of 2021, as well as present those findings at an appropriate medical conference.
High Rates of MS Relapse after TNFα Inhibitor Discontinuation: Spencer Hutto, MD
The fellow of autoimmune neurology at Massachusetts General Hospital discusses the ongoing question about whether the demyelination is an unmasking of disease or consequence of the treatment.
Phase 1b Study of Investigational Parkinson Disease Agent YTX-7739 Announced
Additionally, the therapy’s developer Yumanity Therapeutics announced the results of a single ascending dose study and enrollment in a multiple ascending dose study.
FDA Accepts NDA for FT218 in Treatment of Narcolepsy Symptoms
Avadel’s investigational therapy for excessive daytime sleepiness and cataplexy in narcolepsy has an action date set for October 15, 2021.
Predicting MS Disability With IL-1 Receptor Antagonist Levels: Stephanie Blandford, MSc
The PhD candidate at the neuroimmunology laboratory at Memorial University of Newfoundland discussed her team’s investigations into the use of IL-1RA as a biomarker for MS disability.
NeuroVoices: Dylan Rice, on Improving Adherence to MS DMTs
The clinical research coordinator at Massachusetts General Hospital discussed his presentation from ACTRIMS 2021 on electronic pill bottle monitoring to promote MS medication adherence.
Risdiplam Efficacious in Infants with Spinal Muscular Atrophy Type 1
The FIREFISH clinical trial by PTC Therapeutics is 1 of several studies underway evaluating risdiplam in SMA.
FDA Provides Feedback on NurOwn ALS Therapy, Requests More Data
The recommendation stems from recently published topline data which demonstrated a clinically meaningful treatment response compared to placebo but failed to meet statistical significance.
The Kenneth P. Johnson Memorial Lecture and the Clinical Course of MS: Benjamin Segal, MD
The chair of the Department of Neurology and the director of the Neuroscience Research Institute at The Ohio State University discussed his lecture at ACTRIMS Forum 2021.
Education is Key to Optimum MS Care & Management
June Halper, chief executive officer of the Consortium of Multiple Sclerosis Centers, provides an inside perspective on MS education during MS Awareness Month.
Relivion Noninvasive Neuromodulation System Cleared for Acute Migraine
The headset system from Neurolief was approved based on the findings of a clinical trial of 131 patients with migraine who utilized the device in treatment sessions of up to 1 hour.
Expanding Research in Autoimmune Encephalitis: Divyanshu Dubey, MBBS
The assistant professor of neurology at Mayo Clinic provided his thoughts on the next steps in understanding autoimmune encephalitis and the direction that research must pivot to.
Remote Technology Improves Adherence Rates in Relapsing MS
The authors expanded upon the notion that nonadherence to oral DMTs is more nuanced than simply missing doses.
IL-1RA Biomarker Predicts Disability in Multiple Sclerosis
The researchers found that interleukin-1 receptor antagonist levels in plasma correlated with neurofilament light levels in cerebrospinal fluid.
Cladribine Personalized Dosing Well Tolerated and Efficacious in Multiple Sclerosis
Researchers found that 22 of 23 patients with elevated CSF NfL at baseline had normal levels at 2-year follow-up.
CNM-Au8 as a Novel Therapeutic Category in MS: Robert Glanzman, MD
The chief medical officer at Clene Nanomedicine discussed the recently presented data on CNM-Au8 from the VISIONARY-MS trial.
